there will be a clear clinical impact for the 1 or 2 patients with an NTRK fusion that an oncologist will treat with a TRK inhibitor during their career. Now that I
论文标题:NTRK fusion-positive cancers and TRK inhibitor therapy 作者:Emiliano Cocco, Maurizio Scaltriti, Alexander Drilon 期刊:Nature Reviews Clinical Oncology 发表时间:2018/10/17 数字识别码:10.1038/s41571-018-0113-0 摘要:NTRK gene fusions involving either NTRK1, NTRK2 or NTRK3 (encoding the ...
Zurletrectinib is active against 1st-generation TRK inhibitor resistance mutations in vitro Selitrectinib and repotrectinib are both next-generation TRK inhibitors specifically developed to maintain activity against on-target mutations that are acquired on progression to 1st-generation TRK inhibitors. ...
Larotrectinib is a first-in-class, central nervous system (CNS)-active, highly selective tropomyosin receptor kinase (TRK) inhibitor approved for pediatric and adult patients (pts) with TRK fusion-positive cancer, demonstrating an objective response rate (ORR) of 88% across 78 pediatric pts ...
Additionally, the TRK inhibitor larotrectinib is actually under investigation as single-agent in a phase II NAVIGATE basket trial on NTRK fusion-positive solid cancers, including advanced CCAs (NCT02576431). Moreover, secondary mutations following treatment with TRK inhibitors may cause resistance to...
第15卷 第12 期 2017 年 12 月 临床药物治疗杂志 Clinical Medication Journal Vol.15,No.12 Dec,2017 新药咨讯 国家应急防控药物工程技术研究中心 学术支持 Trk 小分子激酶抑制剂研究进展 2017 年 12 月下旬,拜耳公司和 Loxo Oncology 公司合作开发的口服选 择性原肌球蛋白相关激酶 (Tropomyo- sin-related ...
So larotrectinib is a TRK inhibitor. And so, some of the adverse events that we see are part of this class of agents and related to TRK inhibition, and those include some neurologic adverse events like fatigue and dizziness. We also will occasionally see patients when we discontinue this...
The TKI [tyrosine kinase inhibitor] therapies should be the first-line approach for all patients with NTRK fusion–positive cancer. Larotrectinib [Vitrakvi] is probably a little more active and powerful. The response rates are amazing, along with the duration of response activity in the brain....
[1]Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update Bryan J. Schneider, Jarushka Naidoo, Bianca D. Santomasso, Christina Lacchetti, Sherry Adkins, Milan Anadkat, Michael B. Atkins, Kelly J. Brassil, Jeffrey M. Caterin...
The first-in-class, central nervous system (CNS)-active, highly selective tropomyosin receptor kinase (TRK) inhibitor, larotrectinib, is currently approved for both pediatric and adult patients who haveTRKfusion-positive cancer. Larotrectinib previously demonstrated an objective response rate (...